{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:23:38Z","timestamp":1783405418442,"version":"3.54.6"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Eli Lilly Japan K.K","award":["JP21ek0410086h0001"],"award-info":[{"award-number":["JP21ek0410086h0001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore the patient-reported outcomes (PROs) associated with work productivity and activity impairment (WPAI) in patients with rheumatoid arthritis (RA) in clinical remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We enrolled patients with RA \u226518\u2009years and with a simplified disease activity index \u22643.3 from the Institute of Rheumatology, Rheumatoid Arthritis data set collected in October 2017. The pain-visual analogue scale, patients\u2019 global assessment visual analogue scale (VAS), Japanese version of the Healthcare Assessment Questionnaire (J-HAQ) Disability Index, and duration of morning joint stiffness were selected as the PROs. To evaluate work productivity and activity, the WPAI for RA instrument (WPAI-RA) was used. To assess the contribution of each PRO to the WPAI-RA score, an analysis of variance model was constructed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean age of the 2614 patients was 62.4\u2009years; 85.1% were female. Median values of the WPAI-RA score were 1.1% for absenteeism, 6.5% for presenteeism, 7.4% for work impairment, and 10.2% for activity impairment. Morning joint stiffness contributed the most to absenteeism (18.0%), while pain-VAS contributed the most to presenteeism (57.4%), work productivity loss (51.1%), and daily activity impairment (53.7%). J-HAQ was the second most contributing factor to presenteeism (17.4%), work productivity loss (16.3%), and daily activity impairment (26.0%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The pain-VAS and J-HAQ highly contributed to WPAI in patients with RA in clinical remission.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac105","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T16:11:04Z","timestamp":1662999064000},"page":"899-905","source":"Crossref","is-referenced-by-count":6,"title":["Association between patient-reported outcomes and impairments in work and activity in patients with rheumatoid arthritis in clinical remission: A retrospective analysis using the IORRA database"],"prefix":"10.1093","volume":"33","author":[{"given":"Ryoko","family":"Sakai","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Institute of Rheumatology, Tokyo Women\u2019s Medical University Hospital , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-326X","authenticated-orcid":false,"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Rheumatology, Tokyo Women\u2019s Medical University Hospital , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Showa University Research Administration Center, Showa University Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Sato","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. , Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. , Kobe, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Ikari","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Rheumatology, Tokyo Women\u2019s Medical University Hospital , Tokyo, Japan"},{"name":"Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Department of Orthopedic Surgery, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Rheumatology, Sanno Medical Center , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Institute of Rheumatology, Tokyo Women\u2019s Medical University Hospital , Tokyo, Japan"},{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"2023082610104432400_R1","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113017","article-title":"Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies","volume":"10","author":"Mueller","year":"2021","journal-title":"Cells"},{"key":"2023082610104432400_R2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/14397595.2013.854059","article-title":"Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)","volume":"24","author":"Yamanaka","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2023082610104432400_R3","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2023082610104432400_R4","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s10067-017-3796-1","article-title":"Temporal trends in prevalence, incidence, and mortality for rheumatoid arthritis in Quebec, Canada: a population-based study","volume":"36","author":"Jean","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2023082610104432400_R5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00296-018-04235-y","article-title":"Secular trends in the incidence and prevalence of rheumatoid arthritis within members of an integrated health care delivery system","volume":"39","author":"Kawatkar","year":"2019","journal-title":"Rheumatol Int"},{"key":"2023082610104432400_R6","doi-asserted-by":"crossref","DOI":"10.1186\/ar2669","article-title":"Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases","volume":"11","author":"Gabriel","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2023082610104432400_R7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/occmed\/kqi171","article-title":"Systematic review of studies of productivity loss due to rheumatoid arthritis","volume":"56","author":"Burton","year":"2006","journal-title":"Occup Med (Lond)"},{"key":"2023082610104432400_R8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2014-205393","article-title":"Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the global burden of disease 2010 study and the next steps forward","volume":"74","author":"Hoy","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023082610104432400_R9","first-page":"S72","article-title":"Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis","volume":"30","author":"Furneri","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2023082610104432400_R10","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/137635","article-title":"Work productivity in rheumatoid arthritis: relationship with clinical and radiological features","volume":"2012","author":"Chaparro Del Moral","year":"2012","journal-title":"Arthritis"},{"key":"2023082610104432400_R11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/14397595.2017.1341459","article-title":"Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023082610104432400_R12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","article-title":"A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options","volume":"30","author":"Yamanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2023082610104432400_R13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023082610104432400_R14","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001694","article-title":"All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015\u20132019","volume":"7","author":"Bournia","year":"2021","journal-title":"RMD Open"},{"key":"2023082610104432400_R15","first-page":"2343","article-title":"Improvement and long-term maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis","volume":"34","author":"Mittendorf","year":"2007","journal-title":"J Rheumatol"},{"key":"2023082610104432400_R16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/rheumatology\/39.6.603","article-title":"How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)","volume":"39","author":"Young","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610104432400_R17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard.61.4.335","article-title":"Which patients stop working because of rheumatoid arthritis? Results of five years\u2019 follow up in 732 patients from the Early RA Study (ERAS)","volume":"61","author":"Young","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2023082610104432400_R18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.berh.2004.08.007","article-title":"What are the consequences of early rheumatoid arthritis for the individual?","volume":"19","author":"Scott","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2023082610104432400_R19","article-title":"The impact of disease severity and duration on cost, early retirement and ability to work in rheumatoid arthritis in Europe: an economic modelling study","volume":"4","author":"Galloway","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2023082610104432400_R20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s12325-017-0477-z","article-title":"Impact of adalimumab on work productivity and activity impairment in Japanese patients with rheumatoid arthritis: large-scale, prospective, single-cohort ANOUVEAU study","volume":"34","author":"Takeuchi","year":"2017","journal-title":"Adv Ther"},{"key":"2023082610104432400_R21","first-page":"25","article-title":"Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis","volume":"6","author":"Furuya","year":"2013","journal-title":"J Multidiscip Healthc"},{"key":"2023082610104432400_R22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/art.21661","article-title":"Infliximab treatment maintains employability in patients with early rheumatoid arthritis","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023082610104432400_R23","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/art.23923","article-title":"Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out","volume":"59","author":"Allaire","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023082610104432400_R24","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.24106","article-title":"Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis","volume":"59","author":"Bejarano","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023082610104432400_R25","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1410-1","article-title":"Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"19","author":"Schiff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2023082610104432400_R26","article-title":"Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs","volume":"21","author":"Strand","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2023082610104432400_R27","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2016-209821","article-title":"Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023082610104432400_R28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001040","article-title":"Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB\/IV trial","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2023082610104432400_R29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5271\/sjweh.1298","article-title":"Predictors of sick leave and reduced productivity at work among persons with early inflammatory joint conditions","volume":"34","author":"Geuskens","year":"2008","journal-title":"Scand J Work Environ Health"},{"key":"2023082610104432400_R30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14397595.2017.1416940","article-title":"Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review","volume":"28","author":"Ishida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023082610104432400_R31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/14397595.2016.1205799","article-title":"Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan","volume":"27","author":"Tanaka","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2023082610104432400_R32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-017-3634-5","article-title":"Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort","volume":"36","author":"Shimizu","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2023082610104432400_R33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2023082610104432400_R34","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2023082610104432400_R35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2023082610104432400_R36","doi-asserted-by":"crossref","DOI":"10.4135\/9781412985222","volume-title":"Multivariate Analysis of Variance","author":"Bray","year":"1985"},{"key":"2023082610104432400_R37","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1421-y","article-title":"Large country differences in work outcomes in patients with RA \u2013 an analysis in the multinational study COMORA","volume":"19","author":"van der Zee-neuen","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2023082610104432400_R38","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3899\/jrheum.161404","article-title":"Importance of obtaining remission for work productivity and activity of patients with rheumatoid arthritis","volume":"44","author":"Kim","year":"2017","journal-title":"J Rheumatol"},{"key":"2023082610104432400_R39","first-page":"1729","article-title":"Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis","volume":"35","author":"Zhang","year":"2008","journal-title":"J Rheumatol"},{"key":"2023082610104432400_R40","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/rheumatology\/kep239","article-title":"The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study","volume":"48","author":"Anis","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610104432400_R41","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/rheumatology\/kew056","article-title":"Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate","volume":"55","author":"Emery","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2023082610104432400_R42","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.24828","article-title":"Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis","volume":"61","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023082610104432400_R43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2023082610104432400_R44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/01.mlr.0000204257.25875.04","article-title":"The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work","volume":"44","author":"Li","year":"2006","journal-title":"Med Care"},{"key":"2023082610104432400_R45","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/acr.23619","article-title":"Patient-reported outcomes are more important than objective inflammatory markers for sick leave in biologics-treated patients with rheumatoid arthritis","volume":"70","author":"Olofsson","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac105\/46101740\/roac105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/5\/899\/51269816\/roac105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/5\/899\/51269816\/roac105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T10:11:15Z","timestamp":1693044675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/5\/899\/6696319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,12]]},"published-print":{"date-parts":[[2023,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac105","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2022,9,12]]}}}